Skip to main content
SpringerLink
Log in

Treatment of Advanced-Stage Ovarian Cancer

  • Chapter
  • First Online:
Advances in Diagnosis and Management of Ovarian Cancer

  • 350 Accesses

Abstract

The survival of women with advanced ovarian cancer has recently improved with the use of aggressive surgical debulking, novel chemotherapy regimens including intraperitoneal chemotherapy and the use of targeted chemotherapeutic agents. Currently, women are surviving longer with advanced ovarian cancer and treatment aims to improve quality of life along with increasing survival.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Surveillance, Epidemiology and ER (SEER) Program. SEER*Stat Data-base: incidence-SEER 13 Regs Research DATA. Natl Cancer Institute. Div Cancer Control Popul Sci Surveill Res Progr. 2017;66(1):7–30.

    Google Scholar 

  2. Prat J, FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124:1–5.

    Article  PubMed  Google Scholar 

  3. Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. J Am Med Assoc. 2004;291(22):2705–12.

    Article  CAS  Google Scholar 

  4. Barclay M, Gildea C, Poole J, Hirschowitz L, Menon U, Nordin A. Factors affecting short-term mortality in women with ovarian, tubal, or primary peritoneal cancer. Int J Gynecol Cancer. 2016;26(1):56–65.

    Article  PubMed  Google Scholar 

  5. Allen VA, Takashima Y, Nayak S, Manahan KJ, Geisler JP. Assessment of false-negative ascites cytology in epithelial ovarian carcinoma: a study of 313 patients. Am J Clin Oncol. 2017;40(2):175–7.

    Article  PubMed  CAS  Google Scholar 

  6. Griffiths C. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr. 1975;42:101–4.

    PubMed  CAS  Google Scholar 

  7. Meigs J. Tumors of the female pelvic organs. New York: Macmillan; 1934.

    Google Scholar 

  8. Crusz SM, Chandrasekaran D, Phadnis S, Delvin MJ, Quigley M, Powell ME, et al. Outcome of patients undergoing delayed debulking surgery (DDS) in advanced ovarian cancer (OC). J Clin Oncol. 2018;36(15_Suppl):e17530.

    Article  Google Scholar 

  9. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20(5):1248–59.

    Article  PubMed  Google Scholar 

  10. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RHM, van der Burg MEL, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS, European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in advanced ovarian cancer. N Engl J Med. 2010;363(10):943–53.

    Article  PubMed  CAS  Google Scholar 

  11. Covens AL. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol. 2000;78(3 pt 1):269–74.

    Article  PubMed  CAS  Google Scholar 

  12. Junor EJ, Hole DJ, Gillis CR. Management of ovarian cancer: referral to a multidisciplinary team matters. Br J Cancer. 1994;70(2):363–70.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev. 2011;(8):CD007565.

    Google Scholar 

  14. Qiu L, Yang T, Shan X-H, Hu M-BLY. Metastatic factors for Krukenberg tumor: a clinical study on 102 cases. Med Oncol. 2011;28(4):1514–9.

    Article  PubMed  Google Scholar 

  15. Eisenkop SM, Spirtos NM, Friedman RL, Lin WCM, Pisani AL, Perticucci S. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol. 2003;90(2):390–6.

    Article  PubMed  Google Scholar 

  16. Hoskins WJ, McGuire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 1994;170(4):974–9; discussion 979–980.

    Article  PubMed  CAS  Google Scholar 

  17. Bristow RE, Duska LR, Lambrou NC, Fishman EK, O’Neill MJ, Trimble EL, et al. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer. 2000;89(7):1532–40.

    Article  PubMed  CAS  Google Scholar 

  18. Ferrandina G, Sallustio G, Fagotti A, Vizzielli G, Paglia A, Cucci E, et al. Role of CT scan-based and clinical evaluation in the preoperative prediction of optimal cytoreduction in advanced ovarian cancer: a prospective trial. Br J Cancer. 2009;101(7):1066–73.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. Axtell AE, Lee MH, Bristow RE, Dowdy SC, Cliby WA, Raman S, et al. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J Clin Oncol. 2007;25(4):384–9.

    Article  PubMed  Google Scholar 

  20. Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114(1):26–31.

    Article  PubMed  Google Scholar 

  21. Ataseven B, Grimm C, Harter P, Heitz F, Traut A, Prader S, et al. Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV. Gynecol Oncol. 2016;140(2):215–20.

    Article  PubMed  Google Scholar 

  22. Güenaga KF, Matos D, Wille-Jørgensen P. Mechanical bowel preparation for elective colorectal surgery. Cochrane Database Syst Rev. 2011;2011(9):CD001544.

    PubMed Central  Google Scholar 

  23. Cao F, Li J, Li F. Mechanical bowel preparation for elective colorectal surgery: updated systematic review and meta-analysis. Int J Color Dis. 2012;27(6):803–10.

    Article  CAS  Google Scholar 

  24. Rollins KE, Javanmard-Emamghissi H, Lobo DN. Impact of mechanical bowel preparation in elective colorectal surgery: a meta-analysis. World J Gastroenterol. 2018;24(4):519–36.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Nelson G, Bakkum-Gamez J, Kalogera E, Glaser G, Altman A, Meyer LA, et al. Guidelines for perioperative care in gynecologic/oncology: Enhanced Recovery After Surgery (ERAS) Society recommendations—2019 update. Int J Gynecol Cancer. 2019;29(4):651–68.

    Article  PubMed  Google Scholar 

  26. Saltzman JR, Cash BD, Pasha SF, Early DS, Raman Muthusamy V, Khashab MA, et al. Bowel preparation before colonoscopy. Gastrointest Endosc. 2015;81(4):781–94.

    Article  PubMed  Google Scholar 

  27. Rollins KE, Javanmard-Emamghissi ÃH, Acheson AG, Lobo DN, Frcpe Ã. The role of oral antibiotic preparation in elective colorectal surgery: a meta-analysis. Ann Surg. 2019;270(1):8–10.

    Article  Google Scholar 

  28. Rl N, Gladman E, Barbateskovic M. Antimicrobial prophylaxis for colorectal surgery. Cochrane Database Syst Rev. 2014;2014(5):CD001181.

    Google Scholar 

  29. Morris Melanie S, Graham Laura A, Chu Daniel I, Cannon Jamie A, Hawn MT. Oral antibiotic bowel preparation significantly reduces surgical site infection rates and readmission rates in elective colorectal surgery. Ann Surg. 2015;261(6):1034–40.

    Article  PubMed  CAS  Google Scholar 

  30. World Health Association. Global guidelines for the prevention of surgical site infection. J Hosp Infect. 2016;184.

    Google Scholar 

  31. Lu D, Wang X, Shi G. Perioperative enhanced recovery programs for gynecological cancer patients. Cochrane Database Syst Rev. 2012;12.

    Google Scholar 

  32. Miralpeix E, Nick AM, Meyer LA, Cata J, Lasala J, Mena GE, et al. A call for new standard of care in perioperative gynecologic oncology practice: impact of enhanced recovery after surgery (ERAS) programs. Gynecol Oncol. 2016;141(2):371–8.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Charoenkwan K, Matovinovic E. Early versus delayed oral fluids and food for reducing complications after major abdominal gynaecologic surgery. Cochrane Database Syst Rev. 2014;(12):CD004508.

    Google Scholar 

  34. Armstrong DK, Bundy B, Wenzel L. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34–43.

    Article  PubMed  CAS  Google Scholar 

  35. Markman M, Walker JL. Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J Clin Oncol. 2006;24(6):988–94.

    Article  PubMed  CAS  Google Scholar 

  36. Provencher DM, Gallagher CJ, Parulekar WR, Ledermann JA, Armstrong DK, Brundage M, et al. OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer. Ann Oncol. 2018;29(2):431–8.

    Article  PubMed  CAS  Google Scholar 

  37. Van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230–40.

    Article  PubMed  Google Scholar 

  38. Lim MC, Chang S-J, Yoo HJ, Nam BH, Bristow RPS. Randomized trial of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian, and tubal cancer. J Clin Oncol. 2017;35(Suppl 15):5520.

    Article  Google Scholar 

  39. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. Obstet Gynecol Surv. 2012;67(5):289–90.

    Article  Google Scholar 

  40. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–96.

    Article  PubMed  CAS  Google Scholar 

  41. Ledermann JA. Extending the scope of PARP inhibitors in ovarian cancer. Lancet Oncol. 2019;20(4):470–2.

    Article  PubMed  Google Scholar 

  42. Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18(1):75–87.

    Article  PubMed  CAS  Google Scholar 

  43. Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495–505.

    Article  PubMed  CAS  Google Scholar 

  44. González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391–402.

    Article  PubMed  Google Scholar 

  45. Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386(9990):249–57.

    Article  PubMed  Google Scholar 

  46. Vergote I, Coens C, Nankivell M, Kristensen GB, Parmar MKB, Ehlen T, et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncol. 2018;19(12):1680–7.

    Article  PubMed  Google Scholar 

  47. Fagotti A, Ferrandina G, Fanfani F, Ercoli A, Lorusso D, Rossi M, et al. A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann Surg Oncol. 2006;13(8):1156–61.

    Article  PubMed  Google Scholar 

  48. Angioli R, Palaia I, Zullo MA, Muzii L, Manci N, Calcagno M, et al. Diagnostic open laparoscopy in the management of advanced ovarian cancer. Gynecol Oncol. 2006;100(3):455–61.

    Article  PubMed  Google Scholar 

  49. Gueli Alletti S, Bottoni C, Fanfani F, Gallotta V, Chiantera V, Costantini B, et al. Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial-NCT02324595): a feasibility study. Am J Obstet Gynecol. 2016;214(4):503.e1–6.

    Article  Google Scholar 

  50. Fagotti A, Gueli Alletti S, Corrado G, Cola E, Vizza E, Vieira M, et al. The international mission study: minimally invasive surgery in ovarian neoplasms after neoadjuvant chemotherapy. Int J Gynecol Cancer. 2019;29(1):5–9.

    Article  PubMed  CAS  Google Scholar 

  51. Farghaly SA. Robotic-assisted laparoscopic anterior pelvic exenteration in patients with advanced ovarian cancer: Farghaly’s technique. Eur J Gynaecol Oncol. 2010;31(4):361–3.

    PubMed  CAS  Google Scholar 

  52. Abitbol J, Gotlieb W, Zeng Z, Ramanakumar A, Kessous R, Kogan L, et al. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy. Int J Gynecol Cancer. 2019;2019:1341–7.

    Article  Google Scholar 

  53. von Gruenigen VE, Frasure HE, Reidy AM, Gil KM. Clinical disease course during the last year in ovarian cancer. Gynecol Oncol. 2003;90(3):619–24.

    Article  Google Scholar 

  54. Urbano-Ruiz A, Soares JMJ, da Motta EV, Granuzzo P, Juliao CC, Baracat EC. When to perform palliative surgery in the treatment of ovarian cancer: a brief review. Eur J Gynaecol Oncol. 2013;34(6):532–4.

    PubMed  CAS  Google Scholar 

  55. Kolomainen DF, Daponte A, Barton DPJ, Pennert K, Ind TEJ, Bridges JE, et al. Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC). Gynecol Oncol. 2012;125(1):31–6.

    Article  PubMed  CAS  Google Scholar 

  56. Caceres A, Zhou Q, Iasonos A, Gerdes H, Chi DS, Barakat RR. Colorectal stents for palliation of large-bowel obstructions in recurrent gynecologic cancer: an updated series. Gynecol Oncol. 2008;108(3):482–5.

    Article  PubMed  Google Scholar 

  57. Harter P, Du BA, Hahmann M, Hasenburg A, Burges A, Loibl S, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006;13(12):1702–10.

    Article  PubMed  Google Scholar 

  58. Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the multicenter intergroup study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer. 2011;21(2):289–95.

    Article  PubMed  Google Scholar 

  59. Du Bois A, Vergote I, Ferron G, Reuss A, Meier W, Greggi S, Jensen PT, Selle F, Guyon F, Pomel C, Lecuru F, Zang R, Avall-Lundqvist E, Weon Kim JW, Ponce J, Raspagliesi F, Ghaem-Maghami S, Reinthaller A, Harter P, Sehouli J. Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20. J Clin Oncol. 2017;35:5501.

    Article  Google Scholar 

  60. Du Bois A, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W, et al. Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: final analysis of AGO DESKTOP III/ENGOT-ov20. J Clin Oncol. 2020;38(15_Suppl):6000.

    Article  Google Scholar 

  61. Coleman RL, Enserro D, Spirtos NM, Herzog TJ, Sabbatini P, Armstrong D, Kim B, Fujiwara K, Walker JL, Flynn PJ, Alvarez Secord A, Cohn DE, Brady MF, Mannel RS. A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): a NRG Oncology/Gynecologic Oncology Group (GOG) study. J Clin Oncol. 2018;36:5501.

    Article  Google Scholar 

  62. Son H. Role of FDG PET/CT in staging of recurrent ovarian cancer. Radiographics. 2011;31:569–83.

    Article  PubMed  Google Scholar 

  63. Fagotti A, Fanfani F, Rossitto C, Lorusso D, De Gaetano AM, Giordano A, et al. A treatment selection protocol for recurrent ovarian cancer patients: the role of FDG-PET/CT and staging laparoscopy. Oncology. 2008;75(3–4):152–8.

    Article  PubMed  CAS  Google Scholar 

  64. Holloway RW, Brudie LA, Rakowski JA, Ahmad S. Robotic-assisted resection of liver and diaphragm recurrent ovarian carcinoma: description of technique. Gynecol Oncol. 2011;120(3):419–22.

    Article  PubMed  Google Scholar 

  65. Henretta MS, Anderson CL, Angle JF, Duska LR. It’s not just for laparoscopy anymore: use of insufflation under ultrasound and fluoroscopic guidance by Interventional Radiologists for percutaneous placement of intraperitoneal chemotherapy catheters. Gynecol Oncol. 2011;123(2):342–5.

    Article  PubMed  Google Scholar 

  66. Ivy JJ, Geller M, Pierson SM, Jonson AL, Argenta PA. Outcomes associated with different intraperitoneal chemotherapy delivery systems in advanced ovarian carcinoma: a single institution’s experience. Gynecol Oncol. 2009;114(3):420–3.

    Article  PubMed  CAS  Google Scholar 

  67. Yu J, Liang P, Yu X, Wang Y, Gao Y. Ultrasound-guided percutaneous microwave ablation of splenic metastasis: report of four cases and literature review. Int J Hyperthermia. 2011;27(5):517–22.

    Article  PubMed  CAS  Google Scholar 

  68. Bristow RE, Montz F. Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator. Gynecol Oncol. 2001;83(1):39–48.

    Article  PubMed  CAS  Google Scholar 

  69. Jiao LR, Tierris IAA. A new technique for spleen preservation with radiofrequency. Surgery. 2006;140(3):464–6.

    Article  PubMed  Google Scholar 

  70. Alsop K, Fereday S, Meldrum C, DeFazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian cancer study group. J Clin Oncol. 2012;30(21):2654–63.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  71. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402–16.

    Article  PubMed  CAS  Google Scholar 

  72. Jones MR, Kamara D, Karlan BY, Pharoah PDP, Gayther SA. Genetic epidemiology of ovarian cancer and prospects for polygenic risk prediction. Gynecol Oncol. 2017;147(3):705–13.

    Article  PubMed  CAS  Google Scholar 

  73. Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the international cancer benchmarking partnership): an analysis of population-based cancer registry data. Lancet. 2011;377(9760):127–38.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gynaecological Oncology, The Royal London Hospital, St. Bartholomew’s NHS Trust, Whitechapel, London, UK

    Alexandra Lawrence MD, MRCOG & James Dilley MRCOG

Authors
  1. Alexandra Lawrence MD, MRCOG
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James Dilley MRCOG
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexandra Lawrence MD, MRCOG .

Editor information

Editors and Affiliations

  1. Department of Obstetrics and Gynecology, Joan and Sanford Weill Cornell University Medical Center - New York-Presbyterian Hospital and Sandra and Edward Meyer Cancer Center- Cornell University, New York, NY, USA

    Samir A. Farghaly

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lawrence, A., Dilley, J. (2022). Treatment of Advanced-Stage Ovarian Cancer. In: Farghaly, S.A. (eds) Advances in Diagnosis and Management of Ovarian Cancer. Springer, Cham. https://doi.org/10.1007/978-3-031-09169-8_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-09169-8_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-09168-1

  • Online ISBN: 978-3-031-09169-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation